Features of immunophenotypic finding B-cell lymphoproliferative diseases by flow cytometry

Cover Page

Cite item

Full Text

Abstract

Aim. To assess the information content of conventional and additional immunophenotypic markers (CD200, CD305) in the differential diagnosis B-cell lymphoproliferative diseases by flow cytometry.

Methods. An immunophenotypic study using 4-color flow cytometry was performed in 204 patients with diffe­rent variants of B-cell non-Hodgkin's lymphomas. The study material included peripheral blood and bone marrow. The expression of CD45, CD19, CD20, CD22, CD79b, CD79a, CD5, CD10, CD23, FMC7, CD43, CD38, CD11c, CD103, CD25, CD 200, CD 305, light chains of immunoglobulins (kappa/lambda) using monoclonal antibodies (Becton Dickinson, USA) was evaluated. The intensity of antigen expression was assessed using mean fluorescence intensity (y. e.).

Results. Conventional FMC7-positive expression revealed only half patients with different variants of leu­kemization of non-Hodgkin's lymphomas, whereas atypical positive expression of CD23 was observed in patients with marginal spleen lymphoma and follicular lymphoma in 27.3 and 28.6% of cases, respectively. In mantle cell lymphoma, expression of CD200 in B-cell was detected in a significantly smaller number of observations, accompanied by a significant decrease in the average intensity of CD200 fluorescence compared to B-cell chronic lymphocytic leukemia (B-CLL) cells. The mean fluorescence intensity (MFI) of CD305 in hairy cell leukemia is significantly higher than in splenic marginal zone lymphoma (SMZL) with “villous” lymphocytes.

Conclusion. Different levels of the information content of some conventional markers were revealed in differential immunophenotypic diagnosis of B-cell lymphoproliferative diseases by flow cytometry; the use of additio­nal markers CD200 and CD305 was highly informative in differential diagnostics between different variants of B-cell lymphoproliferative diseases with similar immunophenotypic and morphological characteristics of lymphoid elements.

About the authors

J J Chuksina

Moscow Regional Scientific and Research Clinical Institute named after M.F. Vladimirskiy

Author for correspondence.
Email: tchuxina2009@yandex.ru
Russian Federation, Moscow, Russia

E V Kataeva

Moscow Regional Scientific and Research Clinical Institute named after M.F. Vladimirskiy

Email: tchuxina2009@yandex.ru
Russian Federation, Moscow, Russia

T A Mitina

Moscow Regional Scientific and Research Clinical Institute named after M.F. Vladimirskiy

Email: tchuxina2009@yandex.ru
Russian Federation, Moscow, Russia

References

  1. WHO Classification of Tumours of Haematopoe­tic and Lymphoid Tissues. Ed. S.H. Swerdlow, E. Campo, N.L. Harris et.al. Lyon. 2017; 585 р.
  2. Lugovskaya S.A., Kisilichina D.G., Pochtar M.E. et al. New markers (CD160, CD200, and LAIR-1) in diagnosis of B-cell lymphoproliferative disorders. Klinicheskaya onkogematologiya. Fundamental'nye issledovaniya i klinicheskaya praktika. 2013; 6 (1): 45–53. (In Russ.)
  3. Palumbo G.A., Parrinello N., Fargione G. et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk. Res. 2009; 33 (9): 1212–1216. doi: 10.1016/j.leukres.2009.01.017.
  4. Brunetti L., Di Noto R., Abate G. et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br. J. Haematol. 2009; 145 (5): 665–667. doi: 10.1111/j.1365-2141.2009.07644.x.
  5. Sander B. Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin. Diagn. Pathol. 2011; 28 (3): 245–255. doi: 10.1053/j.semdp.2011.02.010.
  6. Moreaux J., Hose D., Reme T., Jourdan E. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006; 108 (13): 4194–4197. DOI: 101182/blood-2006-06-029355.
  7. Olteanu H., Harrington A.M., Parameswaran H., Kroft S.H. CD200 expression in plasma cell myeloma. Br. J. Haematol. 2011; 153: 408–411. doi: 10.1111/j.1365-2141.­2010.08555.x.
  8. Desoukey N.A., Afify R.A., Amine D.G., Mohammed R.F. CD200 expression in B-cell chronic lymphoproliferative disorders. J. Investig. Med. 2012; 60: 56–61. doi: 10.2310/JIM.0b013e31823908f9.
  9. Brondijk C., de Ruiter T., Ballering J. et al. Crystal structure and collagenbinding site of immune inhibitory receptor LAIR-1: unexpected implications for collagen bin­ding by platelet receptor GPVI. Blood. 2010; 115 (7): 1364–1373. doi: 10.1182/blood-2009-10-246322.
  10. Meyaard L. The inhibitory collagen receptor ­LAIR-1 (CD305). J. Leuk. Biol. 2008; 83: 799–803. doi: 10.1189/Jeb.0907609.
  11. Alfarano A., Indraccolo S., Circosta P. et al. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 1999; 93 (7): 2327–2335. PMID: 10090943.
  12. Krober A., Seiler T., Benner A. et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002 (100): 1410–1416. PMID: 12149225.
  13. Quijano S., López A., Rasillo A. et al. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferativerate of leukemic B-cells in chronic lymphocytic leukemia. Cytometry. Part B. Clin. Cytom. 2008; 74B (3): 139–149. doi: 10.1002/cyto.b.20390.
  14. Muzio M., Scielzo C., Bertilaccio M.T. et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br. J. Haematol. 2009; 144 (4): 507–516. doi: 10.1111/j.1365-2141.2008.07475.x.
  15. Chuksina Y.Y., Yazdovskiy V.V., Shevelev S.V. et al. Prognostic significance of immunophenotypic markers in the evaluation of minimal residual disease in patients with chronic lymphocytic leukemia after immunochemotherapy. Rossiyskiy immunologicheskiy zhurnal. 2015; 9 (3-1): 236–238. (In Russ.)
  16. Katzenberger T., Kalla J., Leich E. et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009; 113 (5): 1053–1061. doi: 10.1182/blood-2008-07-168682.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Expression of CD200 on B-cells in chronic lymphocytic leukemia, reactive lymphocytosis, and mantle cell lymphoma (MCL): A — chronic lymphocytic leukemia, expression of CD200 on 94% of B-chronic lymphocytic leukemia cells, fluorescence intensity (MFI) 350 RU; B — reactive lymphocytosis, expression of CD200 on 0.12% of B cells, MFI = 112.1 RU; C — MCL, expression of CD200 on 1.22% B-lymphocytes (negative), MFI = 57.9 RU; D — MCL, expression of CD200 on 82.9% of B-lymphocytes (positive), MFI = 115.4 RU.

Download (47KB)
Indexing metadata
3. Fig. 2. Expression of CD10 on B-lymphoid elements in follicular lymphoma and blastoid variant of mantle cell lymphoma: A — follicular lymphoma, expression of CD10 on 68.12% of B-cells, fluorescence intensity is 105.4 RU; B — mantle cell lymphoma, blastoid variant, CD10 expression on 55.5% of B-cells, fluorescence intensity was 88.1 RU.

Download (57KB)
Indexing metadata
4. Fig. 3. Expression of CD305 (LAIR-1) on B-lymphocytes with hairy cell leukemia (HCL) and splenic marginal zone lymphoma (SMZL): A — HCL, heterogeneous expression of CD305 on 94.5% of B cells, MFI = 1404 RU; B — SMZL, expression of CD305 on 59.3% of B cells, fluorescence intensity of 320.5 RU.

Download (50KB)
Indexing metadata

© 2020 Chuksina J.J., Kataeva E.V., Mitina T.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies